Mitchell Sokoloff, MD, chair and professor of urology, spoke to WBZ TV’s Dr. Mallika Marshall about a new protest cancer vaccine in a phase III clinical trial at UMass Medical School. Prostate cancer is the leading cancer among men and is treatable, but recurrences are common. The novel vaccine is design to reduce those recurrences.
With a $7.5 million grant from the Paul G. Allen Family Foundation, UMass Medical School will lead a team of academic partners to provide a comprehensive relief effort in Liberia, bringing doctors, nurses and training and medical supplies to the Ebola-stricken country.
Joyce A. Murphy, MPA, executive vice chancellor of Commonwealth Medicine, received the Outstanding Leadership award from the Massachusetts Health Council. Murphy was honored for her work increasing access to health care for high-risk populations.
A team of international scientists led by John Landers, PhD, has shown that TUBA4A, the gene encoding the Tubulin Alpha 4A protein, is associated with the familial form of the neurodegenerative disease, amyotrophic lateral sclerosis.
UMMS celebrated the opening of a new headquarters for Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, among them Phillip Zamore, PhD, and Guangping Gao, PhD.
With a new $7.9 million program project grant from the National Institutes of Health, drug resistance expert Celia Schiffer, PhD, hopes to shift the drug development paradigm by putting resistance first in drug design strategies.
Edward Ginns, MD, PhD, has discovered that a rare genetic dwarfism called Ellis van-Creveld (EvC) syndrome protects against bipolar affective disorder, according to a story in the Boston Globe.
Two UMMS events, the Be Mentally Well community lecture series on Oct. 21 and the first-of-its-kind food addiction conference on Oct. 22, will shed light on the latest science about the biology, diagnosis and treatment of food addiction.
An international group of scientists led by Gang Han, PhD, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.
Gyongyi Szabo, MD, PhD, professor of medicine and vice chair for research in the Department of Medicine, was inducted into the Hungarian Academy of Sciences on Wednesday, Oct. 15.